Most Read Articles
6 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
Yesterday
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Roshini Claire Anthony, 5 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

5 days ago
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.

Vitamin D therapy improves sexual function in women

30 Apr 2019
Women may actually avoid cancer with higher levels of Vitamin D.

A recent study has shown the efficacy of vitamin D therapy in improving sexual function in women with sexual dysfunction and vitamin D deficiency. Moreover, an improvement in depression symptoms does not appear to facilitate this effect.

Women aged 18–45 years with sexual dysfunction, defined as a Female Sexual Functioning Index (FSFI) score <26.55, and serum 25[OH]D <30 ng/ml were recruited in this randomized, double-blind, placebo-controlled trial that examined the effect of vitamin D therapy on sexual function.

Participants received either an intramuscular injection of 300,000 IU cholecalciferol or a placebo at baseline and then after 4 weeks. FSFI was used to assess sexual function at baseline and at 4 and 8 weeks. The authors measured the serum level of 25[OH]D and evaluated depression symptoms using the Beck Depression Inventory (BDI) at baseline and 8 weeks.

There were 38 women in each group who completed the study. Only those in the cholecalciferol group showed an increase in serum 25[OH]D levels by a mean of 14.4±3.2 ng/ml (p<0.001).

The intervention group also registered a higher FSFI score compared with the placebo group at week 4 (19.6 vs 16.3; p=0.002) and week 8 (25.0 vs 17.1; p<0.001). A significant reduction in BDI score was achieved by participants in the cholecalciferol group (mean, –21.0±12.3; p<0.001).

“The effect of treatment on sexual function was independent of its effect on depression symptoms,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
Yesterday
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Roshini Claire Anthony, 5 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

5 days ago
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.